Scynexis (SCYX) Cash from Financing Activities (2013 - 2026)
Scynexis (SCYX) reported Cash from Financing Activities of $24.0 million for Q1 2026, up 270.68% on a YoY basis from $6.5 million in Q1 2025, and up 21002.61% quarter-over-quarter from -$115000.0 in Q4 2025.
Scynexis (SCYX) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Scynexis has reported Cash from Financing Activities for 14 years, with the latest figure at $24.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 270.68% year-over-year to $24.0 million; the trailing twelve-month figure through Mar 2026 stood at $24.0 million (up 268.58% YoY), and the FY2025 full-year result was -$14.2 million, down 10094.24% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $24.0 million, up from -$115000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $42.1 million in Q2 2022, with the low at -$36.6 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $1.5 million across 5 years, with a median of $3500.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 9569.01% — and 2025, when it plunged 93793.33%.
- Scynexis' Cash from Financing Activities stood at -$183000.0 in 2022, then grew by 26.23% to -$135000.0 in 2023, then dropped by 14.81% to -$155000.0 in 2024, then increased by 25.81% to -$115000.0 in 2025, then jumped by 21002.61% to $24.0 million in 2026.
- The last three Cash from Financing Activities figures came in at $24.0 million (Q1 2026), -$115000.0 (Q4 2025), and $29000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Scynexis | 225.23 Mn | 165.97 Mn | - | 24.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.04 Mn |
| Mar 31, 2026 | 24.04 Mn |
| Dec 31, 2025 | -115,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Mar 31, 2025 | -14.08 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -155,000.00 |
| Dec 31, 2024 | -155,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Dec 31, 2023 | -135,000.00 |
| Dec 31, 2023 | -135,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Jun 30, 2023 | -36.64 Mn |
| Jun 30, 2023 | -36.64 Mn |